S
Overview
Synergy Bioscience provides CRDMO/CDMO services for pharma, biotech, and medical devices. It supports the product lifecycle with fee-for-service work, including method development and validation, analytical testing, biocompatibility studies, residual solvent analysis, and clinical research to move products from concept to market. The firm differentiates itself by serving small-to-mid-sized companies with cost-effective, high-quality, end-to-end laboratory and regulatory support across USP/EP/ISO standards. Its goal is to be a dependable technical partner that helps clients navigate regulatory requirements and bring products to market.
Work here?Claim your company
Simplify's take
What believers are saying
- October 2026 site updates signal active marketing and service expansion.
- Clinical research, pharmacovigilance, and biomarker offerings widen wallet share across trials.
- Minority-owned small-disadvantaged status helps win supplier diversity contracts in 2026 procurement cycles.
What critics are saying
- Public signals stop at website updates; 2026 investor or customer expansion remains undisclosed.
- Dallas concentration creates execution risk if one facility loses FDA or ISO credibility.
- Generic CRDMO positioning faces Fierce Medtech, Charles River, and regional labs on price.
What makes synergy unique
- Synergy Bioscience combines CRDMO, testing, and compliance services under one Dallas hub.
- Its 2026 website updates show integrated clinical research and manufacturing positioning.
- Founder-built lab operations target smaller pharma clients needing lower-cost regulated development.
Help us improve and share your feedback! Did you find this helpful?